Solvent-free microwave-assisted synthesis of novel pyrazolo[4′,3′:5,6]pyrido[2,3-d]pyrimidines with potential antifungal activity  by Acosta, Paola et al.
Arabian Journal of Chemistry (2016) 9, 481–492King Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESolvent-free microwave-assisted synthesis of novel
pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidines with
potential antifungal activity* Corresponding author. Fax: +57 2 3339240.
E-mail address: jairo.quiroga@correounivalle.edu.co (J. Quiroga).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2015.03.002
1878-5352 ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Paola Acosta a, Braulio Insuasty a, Alejandro Ortiz a, Rodrigo Abonia a,
Maximiliano Sortino b, Susana A. Zacchino b, Jairo Quiroga a,*a Heterocyclic Compounds Research Group, Department of Chemistry, Universidad del Valle, A.A. 25360 Cali, Colombia
b A´rea Farmacognosia, Facultad de Ciencias Bioquı´micas y Farmace´uticas, Universidad Nacional de Rosario, Suipacha 531,
2000 Rosario, ArgentinaReceived 18 December 2014; accepted 8 March 2015
Available online 17 March 2015KEYWORDS
Pyrazolopyridopyrimidines;
o-Aminonitriles;
Cyanopyridines;
Microwave irradiation;
Antifungal activityAbstract Novel fused pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidines 5 were prepared by a solvent-free
microwave assisted reaction of heterocyclic o-aminonitriles 3 and cyanopyridines 4 in the presence
of tBuOK as catalyst. This protocol provides a versatile procedure for the synthesis of the title
compounds with the advantages of easy work-up, mild reaction conditions and good yields. All
compounds were also tested for antifungal properties against two clinically important fungi;
Candida albicans and Cryptococcus neoformans. Several compounds showed moderate activity
against both fungi, being 5a the most active compound. Analysis of the antifungal behavior of
properly grouped compounds allowed to determine that the position of the N in the pyrimidyl
moiety per se does not play a role in the activity. In turn, the type of 4-R substituent appears to
inﬂuence the activity. In addition to the above considerations, the lipophilicity of compounds mea-
sured as logP showed to be not related to the activity and regarding the dipole moment (D), no net
correlation was observed, although it is the most active compounds (% inhibition >50%) that have
a DP 7.5, mainly against C. albicans.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The pyrimidine core has been widely studied due to its
presence in numerous natural products and structurally diverse
synthetic derivatives (Lawen, 2003; Choudhury et al., 2008).
Among pyrimidine-containing compounds, fused pyrimidines,
particularly pyrido[2,3-d]pyrimidine derivatives (i.e.
deazapteridines) have attracted much attention because they
showed interesting bioactivities (Lunt et al., 1984; Bagley
482 P. Acosta et al.et al., 2001; Devi et al., 2003; Devi et al., 2004; Kanth et al.,
2006; Bulicz et al., 2006; Tu et al., 2006; Tu et al., 2008) such
as antipyretic, antibacterial, antitumor, antihistaminic (Piper
et al., 1986; Kuyper et al., 1996; Quintela et al., 1997;
Cordeu et al., 2007), diuretic, antifolate, calcium-channel-
antagonist, anti-inﬂammatory (Parish et al., 1982; Pastor
et al., 1994; Rosowsky et al., 1995).
The pyrimido[2,3-d]pyrimidine-7-ones I, piritrexim (II) and
[1-(2-amino-6-aryl-pyrido[2,3-d]pyrimidin-7-yl)ureas] (III)
showed to be inhibitors of cyclin-dependent kinases
(Toogood, 2001), dihydrofolate reductase (Gangjee et al.,
2003; Chan and Rosowsky, 2005; Chan et al., 2005) and recep-
tor and non-receptor tyrosine kinases (Hamby et al., 1997;
Dorsey et al., 2000; Wissing et al., 2004), respectively (Fig. 1).
The incidence of fungal infection has increased dramatically
in recent years. The widespread use of antifungal drugs and
their resistance against fungal infections has led to serious
health hazards (Tandon et al., 2009). Although there are
diverse available drugs for the treatment of systemic and
superﬁcial mycoses, they are not completely effective for their
eradication (Brown and Wright, 2005). In addition, they all
possess a certain degree of toxicity and quickly develop resis-
tance due to the large-scale use. There is, therefore, an urgent
need for new antifungal chemical structures alternatives to the
existing ones (Mukherjee et al., 2003). In this sense, the
pyrido[2,3-d]pyrimidine ring system is present in biologically
active compounds which possess high antifungal properties.
More speciﬁcally some of them show activity against dermato-
phytes, fungi causing the most important superﬁcial mycoses
in human beings (Quiroga et al., 2006).
Microwave irradiation (MWI) has emerged as a powerful
tool for high-throughput organic synthesis. This source of
energy can improve the yield and purity of the desired com-
pounds in short reaction times through the precise control of
parameters such as power irradiation, pressure and tempera-
ture (Martins et al., 2009; Kappe, 2004; Quiroga et al., 2010;
Quiroga et al., 2012).N N
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Scheme 1 Synthesis of heterocyclicDue to our interest in the synthesis of potentially bioactive
nitrogen-containing six-membered heterocyclic compounds
(Insuasty et al., 2008; Insuasty et al., 2010; Quiroga et al.,
1998), herein we report a versatile and efﬁcient method for
the preparation of pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidine
derivatives, via cyclocondensation reaction between
heterocyclic o-aminonitriles 3 and cyanopyridines 4. The start-
ing o-aminonitriles 3 (6-aminopyrazolo[3,4-b]pyridine-5-car-
bonitriles) were obtained by a modiﬁed method described in
the literature (Quiroga et al., 1999), through the interaction
of 5-amino-3-methyl-1-phenylpyrazole 1 with different ben-
zylidenemalononitriles 2, using ethanol as solvent and acetic
acid as catalyst (Scheme 1).
2. Results and discussion
2.1. Chemistry
In our study, several conditions were tested at ﬁrst including
diverse solvents, temperatures and power of the microwave
source in order to ﬁnd the best reaction conditions for the
synthesis of 5a. In all cases, reactions were carried out from
o-aminonitrile 3a (R = Cl) and 4-cyanopyridine 4 as a model
reaction (Scheme 2). When ethanol was used as the solvent
and the mixture was subjected to reﬂux, the desired product
5a was obtained in low yield (30%, entry 1) after 9 h. When
DMF was used as the reﬂuxing solvent, almost the same yield
was obtained (31%, entry 2) after 8 h. Signiﬁcative improve-
ments were obtained when the reaction was performed under
MWI using DMF as the solvent (11 min, yield = 36%, entry
3) or under solvent-free MWI (10 min, yield = 41%, entry
4). The presence of tBuOK in the reaction media, which is a
typical catalyst for such reactions (Olivieria et al., 2008),
increased the efﬁciency of the MW as well as the reﬂux reac-
tions. In MW under solvent-free conditions or with solvents
or in reﬂux reactions, the improvement was evidenced forN
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Scheme 2 Synthesis of pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidine derivatives 5.
Table 2 Synthesis of pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidi-
nes 5.
Compound R Product Time (min) Yield (%)
5a Cl Pyridin-4-yl 5 61
5b Cl Pyridin-3-yl 1 57
5c Cl Pyridin-2-yl 1 42
5d OCH3 Pyridin-4-yl 2 60
5e OCH3 Pyridin-3-yl 3 61
5f OCH3 Pyridin-2-yl 2 42
5g CH3 Pyridin-4-yl 5 62
5h CH3 Pyridin-3-yl 6 56
5i CH3 Pyridin-2-yl 3 48
Solvent-free microwave-assisted synthesis of novel pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidines 483shorter times of reaction and higher yields (compares entries 4/
5; 3/10; 1/8; 2/9). Another important ﬁnding was that when
the MW potency is raised in the presence of tBuOK (entries
5–7), shorter times and higher yields were obtained (Table 1).
It is worth mentioning that the lower yields were obtained
when using 2-cyanopyridine in all cases (Table 2).
Formation of the pyrazolo[40,30:5,6]pyridine[2,3-d]pyrim-
idine system was unequivocally established by NMR data of
the products. The chemical shifts and multiplicities of the
protons were in accordance with the expected values. For
example signals for the protons of the phenyl and pyridine
rings of compounds 5 were found between 7.05 and
9.60 ppm. The signal for NH2 appears as a broad singlet
between 5.12 and 5.40 ppm, and the signals of the protons of
CH3 appear as singlets between 1.70 and 1.90 ppm.
A possible mechanism of this cyclo-condensation reaction
is outlined in Scheme 3. Presumably, the initial step is the
addition of the amino group of the o-aminonitrile 3 to the
nitrile group of the cyanopyridine 4 to amidine intermediate
6; the ﬁnal step should be the amine–nitrile intramolecular
condensation in 6 to afford 5a–k (Scheme 3).
2.2. Antifungal activity
In order to have a look into the potential usefulness of these
compounds as hits and heads of series for the development
of antifungal drugs, we investigated the antifungal propertiesTable 1 Optimization of the reaction of the 6-amino-4-(4-
chloro-phenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-
5-carbonitrile 3a with 4-cyanopyridine 4.
Entry Solvent Conditions Time
(min)
Yield
(%)
1 Ethanol Reﬂux 540 30
2 DMF Reﬂux 480 31
3 DMF MW (80 C, 100 W) 11 36
4 Solvent-free MW (100 C, 150 W) 10 41
5 Solvent-free tBuOK, MW
(100 C, 150 W)
8 52
6 Solvent-free tBuOK, MW
(100 C, 200 W)
6 59
7 Solvent-free tBuOK, MW
(100 C, 250 W)
5 61
8 Ethanol tBuOK, Reﬂux 240 36
9 DMF tBuOK, Reﬂux 210 40
10 DMF tBuOK, MW
(80 C, 100 W)
9 48
5j 3,4-OCH2O Pyridin-4-yl 5 59
5k 3,4-OCH2O Pyridin-3-yl 5 50of compounds 5a–5k against two clinical important fungal spe-
cies, Cryptococcus neoformans and Candida albicans. At ﬁrst
we used standardized strains of the American Type Culture
Collection (ATCC) as the targets for testing antifungal activity
and then, the most active compounds were tested against an
expanded panel of clinical isolates in order to know the actual
activity of the selected compounds against not only fungi from
culture collections but from patients with fungal infections.
Results were expressed as the percentages of inhibition of
each fungus in the range 250–0.98 lg/mL by using the stan-
dardized microbroth dilution method M-27A3 of Clinical
and Laboratory Standards Institute (CLSI document, 2008),
which assures conﬁdent and reproducible results.
The selection of C. neoformans was due to the fact that this
opportunistic fungus is the main cause of cryptococcal menin-
goencephalitis, which has a high mortality rate among patients
with profoundly impaired infections (Trpkovie´ et al., 2012).
Scheme 3 Possible mechanistic route for the synthesis of compounds 5.
484 P. Acosta et al.Even though new antifungal drugs have been developed in
recent years, the availability of antifungal agents with
anticryptococcal activity is still limited and sometimes the
strains develop quickly resistance (Perkins et al., 2005). This
scenario has motivated the search of new compounds that pre-
sent antifungal properties against this fungus (Aguiar et al.,
2012).
In turn, C. albicans is the fourth leading cause of nosoco-
mial bloodstream infection (BSI) in intensive care units, caus-
ing fatal invasive candidiasis in a high percentage of patients
(Pfaller and Diekema, 2007). As a consequence, new chemical
structures with anticandidal activities are highly welcome.
For a more comprehensive analysis of the results, we
grouped the compounds in two series: series (i) includes com-
pounds with different pyridinyl moieties (pyridin-4-yl, 3-yl
and 2-yl) and same R (Cl, OCH3 CH3 or 3,4-OCH2O) which
allowed to have a look on the inﬂuence of the position of
the N of the pyridinyl moiety on the antifungal activity; and
series (ii) that includes compounds with same pyridinyl moiety
(pyridin-4-yl, 3-yl or 2-yl) but different R (Cl, OCH3 CH3 and
3,4-OCH2O) which allowed to analyze the role played by the
different R substituents in the antifungal activity.
Compounds of series (i) were sub-divided in four sub-groups:
(i.1) with R = Cl (5a, 5b, 5c); (i.2) with R = OCH3 (5d, 5e,
5f); (i.3) with R = CH3 (5g, 5h, 5i) and (i.4) with R = 3,4-
OCH2O (5j, 5k). Comparative growth inhibition percentages
of the compounds of each sub-group can be observed in Fig. 2.
In Fig. 2, sub-group i.1 (R = Cl) the highest activity was
displayed by 5a which possesses a pyridin-4-yl moiety.
Instead, in sub-groups i.2 and i.4 (R = OCH3 and
AOCH2OA respectively) compounds with 4-pyridinyl moiety
showed the lowest activity and compounds with 3-pyridinyl
(5e, 5k) and 2-pyridinyl (5f) moieties were the most active ones.
Compounds of group i.3 show dissimilar behavior against C.
albicans and C. neoformans. From these results it is clear that
the position of the N in pyridinyl moiety per se, does not play a
role in the activity since i.e. compounds with pyridin-4-yl moi-
eties are not the most active structures within each sub-series
against C. albicans or C. neoformans. The same can be
observed for compounds with pyridin-3-yl or 2-yl moieties
(see Table 3 for values of the inhibition percentages).
Then, we tried to investigate the role (if any) played by the
different R substituents in the activity. So, we compared com-
pounds with same pyridinyl moiety (pyridin-4-yl, 3-yl or 2-yl)
but different R (Cl, OCH3 CH3 and 3,4-OCH2O) [series (ii)] as
follows: in Fig. 3, ii.1 we compared the compounds with pyr-
idin-4-yl moiety but different R: 5a (Cl), 5d (OCH3), 5g
(CH3) and 5j (OCH2O) against each fungi; in ii.2, compoundswith pyridin-3-yl moiety 5b, 5e, 5h and 5k and in ii.3,
compounds with pyridin-2-yl moiety 5c, 5f and 5i.
From Fig. 3 (whose percentages of inhibition can be quer-
ied in Table 4), we see that within compounds of group ii.1 5a,
5d, 5g and 5j those with R = Cl (5a) and R = CH3 (5g)
(Fig. 3, ii.1) showed the best activity (91.7% and 57.3% inhibi-
tion growth against C. neoformans and 78.3% and 76.9%
against C. albicans). Since chloro and methyl groups have
nearly the same volume, the size of the substituent and not
its electronic properties would seem to play a role in the
antifungal activity in this ii.1 group. In contrast, within com-
pounds of group ii.2 with pyridin-3-yl moiety, those with
R = OCH3 (5e) and OCH2O (5k) showed the best activity
against both fungi (72.5% and 64.5% against C. neoformans
and 62.2% and 50.2% against C. albicans). The methylated
derivative 5h also showed good activity but only against C.
albicans. Within group ii.3, the substituents appear not to
inﬂuence the antifungal activity since 5c, 5f and 5i show almost
the same activity against C. neoformans and the behavior is dis-
similar with C. albicans.
To deepen this analysis, the quantitative parameters logP
and dipole moment (D) of each compound (5a–5k) were calcu-
lated and correlated with the activity. Both parameters were
calculated using quantum mechanical at semiempirical level
using Mopac, with the parametric method 3 (PM3). The
molecular modeling was prepared using CS Chem-Ofﬁce
Software version 9.0 (Cambridge software) (C.S. Chem
ofﬁce, 2005). It is known that logP (logarithm of the partition
coefﬁcient in a biphasic system, e.g. n-octanol/water) describes
the macroscopic hydrophobicity of a molecule which is a fac-
tor that many times determines its ability to penetrate the
membranes of fungal cells and to reach the interacting sites,
thus inﬂuencing the antifungal activity of compounds (Voda
et al., 2004). D, that is the measure of net molecular polarity,
tell us about the charge separation in a molecule. The larger
the difference in electronegativities of bonded atoms, the larger
the dipole moment.
Table 4 shows logP and D for all compounds tested along
with the percentages of inhibition against both fungi at 250
lg/mL.
To determine if the logP has some inﬂuence in the activity,
this parameter was plotted vs antifungal activity (against C.
neoformans and C. albicans) in Fig. 4.
From Fig. 4, it is clear that logP, that is to say the
lipophilicity of compounds, has no relationship with the
activity, since compounds with the same logP such as 5a and
5b display completely different activities against both C. neo-
formans and C. albicans. Another clear example is the
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Figure 2 Comparative antifungal activities of compounds of series (i) with different pyridin-yl moieties and similar R in position 4: (i.1)
5a, 5b and 5c; (i.2) 5d, 5e and 5f; (i.3) 5g, 5h and 5i; or in 3,4 (i.4): 5j and 5k against Cryptococcus neoformans [C.n.] or Candida albicans
[C.a]. Amphotericin B (Amp) inhibits 100% growth at 1.0 lg/mL against C. albicans and 0.5 lg/mL against C. neoformans (curves of Amp
are not included).
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Table 3 Percentages of inhibition of 5a–5k against C. albicans ATCC 10231 and C. neoformans ATCC 32264 at the range 250–3.9 lg/
mL.
Sub-series Moiety R Cp Concentrations in lg/mL
250 125 62.5 31.25 15.62 7.81 3.9
C. neoformans ATCC 32264
i.1 4-pyridinyl Cl 5a 91.7 ± 2.8 57.3 ± 0.7 49.5 ± 1.6 13.75 ± 1.8 2.17 ± 0.4 0 0
3-pyridinyl Cl 5b 17.5 ± 2.7 16.9 ± 1.8 14.0 ± 1.8 8.4 ± 1.3 3.4 ± 1.7 0 0
2-pyridinyl Cl 5c 81.6 ± 1.9 48.6 ± 0.38 41.1 ± 0.5 18.8 ± 0.31 1.21 ± 0.79 0 0
i.2 4-pyridinyl OCH3 5d 29.9 ± 1.9 19.7 ± 0.6 13.2 ± 1.08 9.04 ± 1.03 0 0 0
3-pyridinyl OCH3 5e 72.5 ± 0.9 20.7 ± 0.4 19.9 ± 1.21 19.7 ± 1.2 7.9 ± 1.4 6.2 ± 1.3 3.6 ± 1.5
2-pyridinyl OCH3 5f 79.7 ± 1.8 51.3 ± 1.5 33.2 ± 1.2 26.1 ± 1.9 19.3 ± 1.9 14.1 ± 1.1 6.9 ± 0.5
i.3 4-pyridinyl CH3 5g 57.3 ± 1.1 33.09 ± 0.3 23.9 ± 0.3 0 0 0 0
3-pyridinyl CH3 5h 24.7 ± 1.4 7.9 ± 2.1 7.2 ± 1.9 6.8 ± 1.9 0 0 0
2-pyridinyl CH3 5i 64.5 ± 2.9 44.6 ± 1.6 35.6 ± 0.9 34.1 ± 1.9 22.9 ± 1.5 19.3 ± 1.1 9.4 ± 1.4
i.4 4-pyridinyl AOCH2OA 5j 12.9 ± 1.1 10.5 ± 0.9 5.9 ± 0.5 4.7 ± 0.3 0 0 0
3-pyridinyl AOCH2OA 5k 64.5 ± 1.5 62.5 ± 1.0 42.8 ± 0.6 40.7 ± 1.1 31.4 ± 1.4 19.5 ± 1.1 0
Amphotericin B at 2 lg/mL 100 100 100 100 100 100 100
C. albicans ATCC 10231
i.1 4-pyridinyl Cl 5a 78.3 ± 0.3 31.0 ± 1.9 18.1 ± 1.7 12.9 ± 1.2 6.9 ± 1.6 5.7 ± 1.4 0
3-pyridinyl Cl 5b 1.85 ± 0.1 0 0 0 0 0 0
2-pyridinyl Cl 5c 8.12 ± 0.7 4.3 ± 0.4 2.3 ± 0.7 1.6 ± 0.4 1.1 ± 0.1 0 0
i.2 4-pyridinyl OCH3 5d 7.3 ± 1.2 3.0 ± 0.6 2.1 ± 0.5 0 0 0 0
3-pyridinyl OCH3 5e 62.2 ± 2.3 27.1 ± 1.1 16.5 ± 1.9 12.6 ± 0.1 0 0 0
2-pyridinyl OCH3 5f 63.8 ± 2.0 23.7 ± 1.8 15.1 ± 0.4 9.4 ± 0.9 6.2 ± 0.7 1.4 ± 0.1 1.4 ± 0.2
i.3 4-pyridinyl CH3 5g 76.9 ± 1.3 25.4 ± 1.5 24.1 ± 1.3 3.4 ± 0.5 0 0 0
3-pyridinyl CH3 5h 58.5 ± 1.3 31.2 ± 1.8 18.4 ± 1.7 17.7 ± 2.8 11.1 ± 1.4 6.3 ± 1.1 5.3 ± 0.4
2-pyridinyl CH3 5i 11.0 ± 0.6 3.2 ± 0.9 1.3 ± 0.1 0 0 0 0
i.4 4-pyridinyl AOCH2OA 5j 22.1 ± 1.5 11.3 ± 0.6 2.9 ± 0.1 1.7 ± 0.1 0.3 ± 0.1 0 0
3-pyridinyl AOCH2OA 5k 50.2 ± 2.1 34.9 ± 1.7 16.2 ± 0.3 7.0 ± 0.1 3.2 ± 0.2 0 0
Amphotericin B 100 100 100 100 100 100 100
486 P. Acosta et al.comparison of activities of 5e and 5d, which have almost the
same logP and different activities.
In turn, to determine if D has some inﬂuence in the activity,
D was plotted vs antifungal activity (against C. neoformans and
C. albicans) in Fig. 5.
In Fig. 5, we can observe that there is not a net correlation
between D and antifungal activity, but it is observed that most
active compounds (% inhibition >50%) have a DP 7.5,
mainly against C. albicans.
From Table 3 and both Figs. 4 and 5, it is clear that com-
pound 5a showed the best activity against both fungi inhibiting
more than 90% of the growth of C. neoformans and 78% of C.
albicans and therefore, this compound deserves further
attention.
2.2.1. Second order studies with clinical isolates
In order to gain insight into the potential of 5a not only
against standardized strains but on clinical isolates of medical
important fungi, 5a was tested at 250, 125, 62.5, 31.2 and
16.2 lg/mL against an extended panel of C. albicans and C.
neoformans strains isolated from immunocompromised
patients suffering fungal infections. Results are recorded in
Table 5.
As it can be observed in Table 5, compound 5a exerts more
than 80% of inhibition on 3 out the 5 C. albicans strains at
250 lg/mL, and more than 50% inhibition in 4 of the 5 strainsat 125 lg/mL. Moreover, compound 5a produces more than
80% inhibition on 8/10 isolates of C. neoformans at 250
lg/mL, more than 50% inhibition in 9/10 isolates at 125 lg/mL
and in 4/10 strains at 62.5 lg/mL, clearly indicating that 5a
is a better inhibitor of C. neoformans than of C. albicans.
3. Conclusion
In this article we described the microwave-assisted synthesis of
novel pyrazolo[40,30:5,6]pyrimido[2,3-d]pyrimidines 5 under
solvent-free conditions. The described synthesis represents a
versatile, practical and environmental friendly method for
the preparation of compounds 5 with the advantages of easy
work-up, mild reaction conditions and good yields.
Regarding the antifungal activity, several compounds showed
moderate activity against C. albicans and C. neoformans, being
5a the most active compound. Analysis of the antifungal activ-
ity of properly grouped compounds allowed to determine that
the position of the N in the pyrimidyl moiety per se does not
play a role in the activity. In turn, the type of 4-R substituent
appears to play a role in the activity. Within compounds with
pyridin-4-yl moiety (5a, 5d, 5g and 5j) those with R = Cl (5a)
and R = CH3 (5g) showed the best activity. In contrast, within
compounds with pyridin-3-yl moiety, those with R = OCH3
(5e) and OCH2O (5k) showed the highest inhibition percentage
against both fungi. Within compounds with pyridin-2-yl, the
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Figure 3 Comparative antifungal activities of compounds of series (ii) with different pyridin-yl moiety and similar 4-R: (ii.1) compounds
with pyridine-4-yl and Cl (5a), OCH3 (5d), CH3 (5g) and 3,4-OCH2O (5j); (ii.2) compounds with pyridine-3-yl moiety 5b (Cl), 5e (OCH3),
5h (CH3) and 5k (3,4-OCH2O); (ii.3) compounds with pyridine-2-yl moiety 5c (Cl); 5f (OCH3); 5i (CH3) against Cryptococcus neoformans
[C.n.] or Candida albicans [C.a.]. Amphotericin B inhibits 100% at 1.0 lg/mL against C. albicans and 0.5 lg/mL against C. neoformans.
Solvent-free microwave-assisted synthesis of novel pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidines 487substituents appear not to exert any inﬂuence in the antifungal
activity. In addition to the above considerations, the lipophilic-
ity of compounds measured as logP showed to be not related
to the activity and there is not observed a net correlation
between D and antifungal activity, although it is observed that
the most active compounds (% inhibition >50%) have a
DP 7.5, mainly against C. albicans.
4. Experimental
Commercially available starting materials, reagents and sol-
vents were used as supplied. The TLC analysis was performedon Merck TLC-plates aluminum silica gel 60 F254. Melting
point was measured using a Bu¨chi melting point apparatus
and was uncorrected. Microwave reactions were performed
in glass vessels (10 mL) using a CEM Focused Microwave
Synthesis System apparatus, Model Discover, with power
output from 0 to 300 W. The IR analysis was performed on
a Shimadzu FTIR 8400 spectrophotometer in KBr disks. 1H
and 13C NMR spectra were run on a Bruker DPX 400 spec-
trometer operating at 400 MHz and 100 MHz respectively,
using dimethyl sulfoxide-d6 as solvent and tetramethylsilane
as internal standard. Mass spectra were obtained from
Shimadzu GCMS-QP 2010 spectrometer (equipped with a
Table 4 The in vitro activity (% inhibition in Cryptococcus
neoformans (C.n.) and Candida albicans (C.a.) at 250 lg/mL of
compounds 5a–k.
Compound LogP Dipole (D) C.n.1 (% Inh) C.a.1 (% Inh)
5a 7.27 7.6032 91.7 78.3
5b 7.27 6.9140 17.5 1.8
5c 7.69 7.1909 81.6 8.1
5d 6.58 8.4704 29.9 7.2
5e 6.58 9.2600 72.5 62.1
5f 7.01 9.2013 79.7 63.7
5g 7.20 8.5322 57.3 76.9
5h 7.20 7.9098 24.7 58.4
5i 7.62 8.6168 64.5 11.0
5j 6.49 7.4864 12.9 22.0
5k 6.46 8.9442 64.4 50.3
488 P. Acosta et al.direct inlet probe) operating at 70 eV. Elemental analysis was
carried out using a Thermo Finnigan Flash EA1112 CHN
(STIUJA) elemental analyzer.
4.1. General procedure for the preparation of
pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidines 5
All experiments were carried out using a focused microwave
reactor (CEM Discover TM). A mixture of ortho-aminonitrile
3 (0.3 mmol), cyanopyridine 4 (0.4 mmol) and tBuOK
(10 mol%), was exposed to microwave irradiation from 1 to
6 min at 100 C, a power of 250 W and 30 PSI of pressure.
Then, the reaction mixture was treated with ethanol and the
excess of solvent was removed under reduced pressure.
Puriﬁcation of products was performed using column chro-
matography in a mixture CHCl3/EtOH (20:1) as eluent.
4.1.1. 4-(4-Chlorophenyl)-3-methyl-1-phenyl-7-(pyridin-4-yl)-
1H-pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidin-5-amine 5a
Yellow solid, yield 61%, mp > 350. FTIR (KBr) t(cm1):
3496 (NH), 3038 (‚CAH), 1600, 1569 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.78 (s, 3H, CH3), 5.13
(brs, 2H, NH2), 7.36 (t, 1H, J = 7.3 Hz, HAp), 7.61 (t, 2H,
J = 7.7 Hz, HAo,), 7.76–7.86 (m, 4H, HAm, HBm), 8.29 (d,Figure 4 LogP vs inhibition percentage of Cryptococcus neoforma2H, J = 4.6 Hz, H-2Py), 8.33(d, 2H, J = 8.1 Hz, HBo), 8.75
(d, 2H, J = 4.7 Hz, H-3Py). 13C NMR (100 MHz DMSO-d6)
d: 14.5 (CH3), 103.6 (C), 116.8 (C), 121.1 (CH), 122.6 (CH),
126.1 (CH), 129.6 (CH), 130.0 (CH), 131.0 (CH), 134.3 (C),
135.7 (C), 139.4 (C), 145.1 (C), 145.2 (C), 145.6 (C), 150.6
(CH), 152.6 (C), 159.6 (C), 162.4 (C), 164.9 (C). HR-MS calcd
for C26H18ClN7 463.1312, found [M
++K] 501.7842.
[M++H] 463.8283. Anal. Calcd for C26H18ClN7ÆH2O: C,
64.90; H, 4.08; N, 20.34; found: C, 65.13; H, 3.82; N, 20.38.4.1.2. 4-(4-Chlorophenyl)-3-methyl-1-phenyl-7-(pyridin-3-yl)-
1H-pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidin-5-amine 5b
Yellow solid, yield 57%, mp: 317–318. FTIR (KBr) t(cm1):
3470 (NH), 3058 (‚CAH), 1550, 1510 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.74 (s, 3H, CH3), 5.10
(brs, 2H, NH2), 7.35 (t, 1H, J = 7.4 Hz HAp), 7.51–7.56 (m,
1H, H-2Py), 7.60 (t, 2H, J = 7.9 Hz, HAo), 7.79 (s, 4H,
HAm, HBm), 8.33 (d, 2H, J = 7.9 Hz, HBo), 8.68–8.73 (m,
2H, H-3Py, H-4Py). 9.55 (s, 1H, H-5Py)
13C NMR
(100 MHz DMSO-d6) d: 14.5 (CH3), 103.4 (C), 116.6 (C),
121.2 (CH), 123.8 (CH), 126.2 (CH), 129.5 (CH), 130.0
(CH), 130.1 (CH), 133.8 (C), 134.8 (C), 135.7 (C), 136.0
(CH), 139.5(C), 145.0 (C), 145.2 (C), 150.2 (CH), 151.8
(CH), 152.3 (C), 159.7 (C), 162.7 (C), 164.7 (C). HR-MS calcd
for C26H18ClN7 463.1312, found [M
++K] 501.8709.
[M++H] 463.9121.4.1.3. 4-(4-Chlorophenyl)-3-methyl-1-phenyl-7-(pyridin-2-yl)-
1H-pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidin-5-amine 5c
Yellow solid, yield 42%, mp > 350. FTIR (KBr) t(cm1):
3485 (NH), 3040 (‚CAH), 1574, 1547 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.70 (m, 3H, CH3), 7.36
(t, 1H, J= 7.3 Hz, HAp), 7.52–7.56 (m, 2H, HAo), 7.61–
7.63 (m, 4H, HAm, HBm), 8.37 (d, 2H, J= 7.8 Hz, HBo),
8.58–8.63 (m, 2H, H-2Py, H-3Py), 8.83–8.70 (m, 2H, H-4Py,
H-5Py). Not observed (brs, 2H, NH2). Compound 5c is barely
soluble in dimethyl sulfoxide or any other solvent normally
used for NMR spectroscopy; thus, made the registration of a
high resolution 13C NMR spectrum impossible. HR-MS calcd
for C26H18ClN7 463.1312, found [M
++Na] 486.1490.
[M++ H] 463.3628.ns (left) and C. albicans (right) growth, by 5a–k at 250 lg/mL.
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Figure 5 Dipole (D) vs inhibition percentage of the C. neoformans (left) and C. albicans (right) growth by 5a–k each at 250 lg/mL.
Table 5 Antifungal activity (inhibition percentage) of 5a against clinical isolates of Candida albicans and Cryptococcus neoformans.
Inhibition % of compound 5a Amp
Strain 250 lg/mL 125 lg/mL 62.5 lg/mL 331.2 lg/mL 15.6 lg/mL 1
Ca ATCC10231 78.3 ± 0.3 31.0 ± 1.9 18.1 ± 1.7 12.9 ± 1.2 6.9 ± 1.6 100
Ca CCC 126 80.1 ± 0.4 58.2 ± 2.1 34.2 ± 1.5 14.3 ± 0.2 5.3 ± 0.6 100
Ca CCC 127 70.8 ± 2.3 45.4 ± 1.0 32.7 ± 1.2 10.7 ± 0.8 4.2 ± 1.0 100
Ca CCC 128 73.3 ± 0.8 55.0 ± 1.6 46.3 ± 1.4 17.4 ± 0.7 12.2 ± 1.3 100
Ca CCC 129 84.3 ± 1.2 62.5 ± 1.1 50.7 ± 1.4 33.9 ± 0.2 10.9 ± 2.0 100
Ca CCC 130 80.2 ± 1.2 53.2 ± 0.4 44.7 ± 1.3 22.5 ± 0.7 12.6 ± 1.3 100
Cn ATCC 32264 91.7 ± 2.8 57.3 ± 0.7 49.5 ± 1.6 13.7 ± 1.8 2.1 ± 0.4 100
Cn IM 983040 94.3 ± 1.4 68.3 ± 3.4 54.9 ± 2.3 23.4 ± 1.2 5.2 ± 0.7 100
Cn IM 972724 97.8 ± 2.4 77.2 ± 2.3 35.5 ± 3.3 13.1 ± 1.3 0.3 ± 0.1 100
Cn IM 042074 84.4 ± 1.7 76.8 ± 1.5 55.9 ± 2.6 33.6 ± 1.8 7.8 ± 1.2 100
Cn IM 983036 92.3 ± 1.3 80.4 ± 1.0 52.4 ± 1.3 32.5 ± 2.4 12.3 ± 1.8 100
Cn IM 00319 88.3 ± 1.2 68.5 ± 1.6 53.7 ± 1.4 39.3 ± 0.2 16.9 ± 2.5 100
Cn IM 972751 83.4 ± 1.9 54.5 ± 1.5 22.7 ± 0.4 13.7 ± 1.3 6.7 ± 0.4 100
Cn IM 031631 74.3 ± 1.5 55.8 ± 3.1 35.1 ± 1.9 15.2 ± 0.2 5.7 ± 0.2 100
Cn IM 031706 87.5 ± 2.1 46.5 ± 1.2 37.1 ± 2.2 28.8 ± 1.2 12.3 ± 1.2 100
Cn IM 961951 79.7 ± 2.8 69.5 ± 2.9 45.6 ± 1.2 20.9 ± 1.2 9.9 ± 0.3 100
Cn IM 052470 88.2 ± 1.7 76.3 ± 1.1 45.3 ± 1.5 31.2 ± 0.3 14.7 ± 1.5 100
For the sake of comparison, standardized strains of C. albicans ATCC 10231 and C. neoformans ATCC 32264 are included in the table. Ca:
Candida albicans; Cn: Cryptococcus neoformans; IM: Instituto Malbra´n, Buenos Aires; ATCC: American Type Culture Collection, Manassas,
USA; CCC: Reference Center in Mycology, Rosario, Argentina. Amp = Amphotericin B.
Solvent-free microwave-assisted synthesis of novel pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidines 4894.1.4. 4-(4-Methoxyphenyl)-3-methyl-1-phenyl-7-(pyridin-4-
yl)-1H-pyrazolo[40,30:5,6]pyrido [2,3-d]pyrimidin-5-amine 5d
Yellow solid, yield 60%, mp: 332–333. t(cm1): 3494 (NH),
3044 (‚CAH), 1620, 1574 (C‚N and C‚C). 1H NMR
(400 MHz, DMSO-d6) d: 1.90 (s, 3H, CH3), 3.94 (s, 3H,
OCH3), 5.13 (brs, 2H, NH2), 7.28 (d, 2H, J = 8.6 Hz, HBo),
7.35 (t, 1H, J = 7.4 Hz, HAp), 7.55–7.63 (m, 4H, HAm,
HBm), 8.32 (d, 2H, J = 5.9 Hz, H-2Py), 8.36 (d, 2H,
J= 7.8 Hz, HAo), 8.75 (d, 2H, J = 5.9 Hz, H-3Py). 13C
NMR (100 MHz DMSO-d6) d: 14.4 (CH3), 56.1 (OCH3),
104.0 (C), 115.6 (CH), 117.6 (C), 121.1 (CH), 122.6 (CH),
126.1 (CH), 127.4 (C), 129.5 (CH), 130.0 (CH), 139.6 (C),
145.4 (C), 145.8 (C), 146.8 (C), 150.6 (CH), 152.4 (C), 159.7
(C), 161.3 (C), 162.4 (C), 165.1 (C). HR-MS calcd for
C27H21N7O 459.1808, found [M
++K] 498.9195. [M+ +H]
459.9754.4.1.5. 4-(4-Methoxyphenyl)-3-methyl-1-phenyl-7-(pyridin-3-
yl)-1H-pyrazolo[40,30:5,6]pyrido [2,3-d]pyrimidin-5-amine 5e
Yellow solid, yield 61%, mp: 306–307. FTIR (KBr) t(cm1):
3468 (NH), 3056 (‚CAH), 1575, 1508 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.81 (s, 3H, CH3), 3.92
(s, 3H, OCH3), 5.26 (brs, 2H, NH2), 7.28 (d, 2H,
J = 8.4 Hz, HBo), 7.36 (t, 1H, J = 7.3 Hz, HAp), 7.51–7.58
(m, 1H, H-3Py) 7.58–7.67 (m, 4H, HAm, HBm), 8.35 (d, 2H,
J = 8.0 Hz, HAo), 8.73 (d, 2H, J = 7.3 Hz, H-2Py, H-4Py),
9.57 (s, 1H, H-6Py). 13C NMR (100 MHz DMSO-d6) d: 14.4
(CH3), 56.1 (OCH3), 103.8 (C), 115.6 (CH), 117.0 (C), 121.1
(CH), 123.7 (CH), 126.1 (CH), 127.5 (C), 129.5 (CH), 130.3
(CH), 133.9 (C), 136.0 (CH), 139.6 (C), 145.4 (C), 146.7 (C)
150.2 (CH), 151.7 (CH), 152.4 (C), 159.7 (C), 161.3 (C),
162.7 (C), 164.9 (C). HR-MS calcd for C27H21N7O 459.1808,
found [M++K] 498.8764. [M++ H] 459.9340.
490 P. Acosta et al.4.1.6. 4-(4-Methoxyphenyl)-3-methyl-1-phenyl-7-(pyridin-2-
yl)-1H-pyrazolo[40,30:5,6]pyrido [2,3-d]pyrimidin-5-amine 5f
Yellow solid, yield 42%, mp > 350. FTIR (KBr) t(cm1):
3484 (NH), 3055 (‚CAH), 1579, 1547 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.86 (s, 3H, CH3), 3.94
(s, 3H, OCH3), 7.27 (d, 2H, J = 8.1 Hz, HBo), 7.35 (t, 1H,
J = 7.6 Hz, HAp), 7.53 (t, 1H, J = 6.2 Hz, H-4Py) 7.61 (d,
4H, J= 7.8 Hz, HAm, HBm), 7.97 (t, 1H, J = 7.8 Hz, H-
3Py), 8.39 (d, 2H, J= 8.1 Hz, HAo), 8.48 (d, 1H,
J = 7.9 Hz, H-2Py), 8.73 (d, 1H, 4.6 Hz, H-5Py). Not
observed (brs, 2H, NH2). Compound 5f is barely soluble in
dimethyl sulfoxide or any other solvent normally used for
NMR spectroscopy; thus, made the registration of a high res-
olution 13C NMR spectrum impossible. HR-MS calcd for
C27H21N7O 459.1808, found [M
++K] 498.9088. [M++ H]
459.9754.
4.1.7. 3-Methyl-1-phenyl-7-(pyridin-4-yl)-4-(p-tolyl)-1H-
pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidin-5-amine 5g
Yellow solid, yield 62%, mp: 339–340. FTIR (KBr) t(cm1):
3498 (NH), 3042 (‚CAH), 1589, 1559 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d:1.82 (s, 3H, CH3), 5.22
(brs, 2H, NH2), 7.36 (t, 1H, J = 7.3 Hz, HAp), 7.49–7.72 (m,
6H, HBo, HAm, HBm), 8.31 (d, 2H, J = 5.2 Hz, H-3Py),
8.35 (d, 2H, J = 8.0 HAo), 8.76 (d, 2H, J = 5.1 Hz, H-2Py).
13C NMR (100 MHz DMSO-d6) d: 14.3 (CH3), 21.4 (CH3),
103.8 (C), 116.9 (C), 121.1 (CH), 122.6 (CH), 126.1 (CH),
128.7 (CH), 129.5 (CH), 130.5 (CH), 132.7 (C), 139.6 (C),
140.4 (C), 145.4 (C), 145.8 (C), 146.8 (C), 150.6 (CH), 152.4
(C), 159.7 (C), 162.5 (C), 165.1 (C). HR-MS calcd for
C27H22N7 443.1858, found [M
++K] 482.8695. [M+ +H]
443.9281.
4.1.8. 3-Methyl-1-phenyl-7-(pyridin-3-yl)-4-(p-tolyl)-1H-
pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidin-5-amine 5h
Yellow solid, yield 56%, mp: 305–306. FTIR (KBr) t(cm1):
3468 (NH), 3054 (‚CAH), 1564, 1547 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.81 (s, 3H, CH3), 5.21
(brs, 2H, NH2), 7.37 (t, 1H, J = 7.3 Hz, HAp), 7.58–7.66 (m,
7H, HBo, HAm, HBm, H-3Py), 8.35 (d, 2H, J = 8.0 Hz,
HAo), 8.69–8.78 (m, 2H, H-2Py, H-4Py), 9.58 (s, 1H, H-6Py)
13C NMR (100 MHz DMSO-d6) d: 14.5 (CH3), 21.5 (CH3),
103.4 (C), 116.6 (C), 120.9 (CH), 124.1 (CH), 126.1 (CH),
128.6 (CH), 129.7 (CH), 130.5 (CH), 132.6 (C), 133.5 (C),
136.1 (CH), 139.3 (C), 140 (C), 145.4 (C), 146.9 (C), 150.0
(CH), 151.9 (CH), 152.0 (C), 159.5 (C), 162.5 (C), 164.7 (C).
EI MS (70 eV): m/z: 443(M+, 18), 354(16), 236 (17). Anal.
Calcd for C27H21N7: C, 73.12; H, 4.77; N, 22.11; found: C,
73.07; H, 4.72; N, 22.06.
4.1.9. 3-Methyl-1-phenyl-7-(pyridin-2-yl)-4-(p-tolyl)-1H-
pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidin-5-amine 5i
Yellow solid, yield 48%, mp > 350. FTIR (KBr) t(cm1):
3481 (NH), 3057 (‚CAH), 1569, 1544 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6): 1.86 (s, 3H), 7.36 (t, 1H,
J= 7.4 Hz, HAp), 7.52–7.57 (m, 4H, HBo, HBm), 7.95–8.01
(m, 2H, HAm), 8.03 (d, 2H, J= 7.7 Hz, H-3Py, H-4Py),
8.39 (d, 2H, J= 7.7 Hz, HAo), 8.63 (d, 2H, J= 4.6 Hz, H-
2Py, H-5Py). Not observed (brs, 2H, NH2). Compound 5i is
barely soluble in dimethyl sulfoxide or any other solvent nor-
mally used for NMR spectroscopy; thus, made the registrationof a high resolution 13C NMR spectrum impossible. EI MS
(70 eV): m/z: 443(M+, 83), 354(1), 236 (1). Anal. Calcd for
C27H21N7: C, 73.12; H, 4.77; N, 22.11; found: C, 73.09; H,
4.74; N, 22.08.
4.1.10. 4-(Benzo[d][1,3]dioxol-5-yl)-3-methyl-1-phenyl-7-
(pyridin-4-yl)-1H-pyrazolo[40,30:5,6] pyrido[2,3-d]pyrimidin-
5-amine 5j
Yellow solid, yield 59%, mp: 316–317. FTIR (KBr) t(cm1):
3488 (NH), 3045 (‚CAH), 1570, 1559 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.82 (s, 3H, CH3), 5.36
(brs, 2H, NH2), 6.15 (s, 2H, OCH2O), 7.06 (d, 1H,
J = 7.8 Hz, HAp), 7.16 (d, 1H, J = 7.9 Hz, HBo), 7.19–7.30
(m, 2H, HBo0, HBm), 7.51 (t, 2H, J= 7.7 Hz, HAm) 8.20–
8.27 (m, 4H, H-2Py, HAo), 8.67 (d, 2H, J = 5.3 Hz, H-3Py).
13C NMR (100 MHz DMSO-d6) d: 14.1 (CH3), 102.0 (CH2),
103.3 (C), 108.9 (CH), 109.1(CH), 116.6 (C), 120.2 (CH),
122.0 (CH), 125.6 (CH), 127.8 (C), 129.2 (CH), 138.8 (C),
144.8 (C), 145.0 (C), 145.9 (C), 148.1 (C), 148.6 (C), 150.1
(CH), 151.4 (C), 158.9 (C), 161.6 (C), 164.3 (C). EI MS
(70 eV): m/z: 473(M+, 46), 369 (61), 313 (23), 236 (30). Anal.
Calcd for C27H19N7O2: C, 68.49; H, 4.04; N, 20.71; found:
C, 68.39; H, 4.01; N, 20.61.
4.1.11. 4-(Benzo[d][1,3]dioxol-5-yl)-3-methyl-1-phenyl-7-
(pyridin-3-yl)-1H-pyrazolo[40,30:5,6] pyrido[2,3-d]pyrimidin-
5-amine 5k
Yellow solid, yield 50%, mp: 325–326. FTIR (KBr) t(cm1):
3478 (NH), 3058 (‚CAH), 1571, 1518 (C‚N and C‚C).
1H NMR (400 MHz, DMSO-d6) d: 1.88(s, 3H, CH3), 5.13
(brs, 2H, NH2), 6.24 (s, 2H, OCH2O), 7.16 (d, 1H,
J = 9.0 Hz, HAp), 7.25 (d, 1H, J = 7.9 Hz, HBo), 7.32–7.38
(m, 2H, HBo0, HBm), 7.46–7.69 (m, 4H, H-2Py, H-3Py,
HAm), 8.34 (d, 2H, J = 8.0 Hz, HAo), 8.72 (t, 2H,
J = 6.1 Hz, H-4PY, H-6Py). 13C NMR (100 MHz DMSO-
d6) d: 14.0 (CH3), 101.9 (CH2), 103.1 (C), 108.9 (CH), 109.1
(CH), 116.3 (C), 120.2 (CH), 122.0 (CH), 123.5 (CH), 125.5
(CH), 127.9 (C), 129.1 (CH), 133.0 (C), 135.5 (CH), 138.8
(C), 144.8 (C), 145.9 (C), 148.1 (C), 148.6 (C), 149.5 (C),
151.4 (CH), 158.9 (C), 161.8 (C), 164.7 (C). EI MS (70 eV):
EI MS: m/z: 473(M+, 100), 368 (11), 313 (12), 236 (19).
Anal. Calcd for C27H19N7O2: C, 68.49; H, 4.04; N, 20.71;
found: C, 68.41; H, 4.02; N, 20.62.
4.2. Biological evaluation
4.2.1. Antifungal activity
4.2.1.1. Microorganisms and media. For the antifungal evalua-
tion, standardized strains from the American Type Culture
Collection (ATCC), Rockville, MD, USA, Reference Center
in Mycology (CEREMIC, CCC, Rosario, Argentina) and
Instituto Malbra´n (IM, Av. Velez Sarsﬁeld 563, Buenos
Aires) were used. Standardized strains: C. albicans ATCC
10231 and C. neoformans ATCC 32264; clinical isolates of C.
albicans were provided by CCC and of C. neoformans were
provided by IM. Voucher specimens of the isolated are
presented in Table 6. Strains were grown on Sabouraud-
chloramphenicol agar slants for 48 h at 30 C, were maintained
on slopes of Sabouraud-dextrose agar (SDA, Oxoid) and
sub-cultured every 15 days to prevent pleomorphic trans-
formations. Inocula were obtained according to reported
Solvent-free microwave-assisted synthesis of novel pyrazolo[40,30:5,6]pyrido[2,3-d]pyrimidines 491procedures [29] and adjusted to 1–5 · 103 cells with colony
forming units (CFU)/mL.
4.2.1.2. Fungal growth inhibition percentage determination.
Broth microdilution techniques were performed in 96-well
microplates according to the guidelines of the Clinical and
Laboratory Standards Institute for yeasts (M27-A3) (Clinical
and Laboratory Standards Institute). Reference Method for
Broth Dilution Antifungal Susceptibility Testing of Yeasts,
Approved Standard [29]. For the assay, compound test wells
(CTWs) were prepared with stock solutions of each compound
in DMSO (maximum concentration 6 1%), diluted with
RPMI-1640, to ﬁnal concentrations of 250–0.98 lg/mL. An
inoculum suspension (100 lL) was added to each well (ﬁnal
volume in the well = 200 lL). A growth control well (GCW)
(containing medium, inoculum, and the same amount of
DMSO used in a CTW, but compound-free) and a sterility
control well (SCW) (sample, medium, and sterile water instead
of inoculum) were included for each fungus tested. Microtiter
trays were incubated in a moist, dark chamber at 30 C for
48 h for both yeasts. Microplates were read in a VERSA
Max microplate reader (Molecular Devices, Sunnyvale, CA,
USA). Amphotericin B was used as positive control. Tests
were performed in triplicate. Reduction of growth for each
compound concentration was calculated as follows: % of
inhibition = 100  (OD 405 CTW  OD 405 SCW)/(OD 405
GCW  OD 405 SCW). The means ± SEM were used for
constructing the dose–response curves representing% inhibi-
tion vs concentration of each compound. Dose–response
curves were constructed with SigmaPlot 11.0 software.Acknowledgements
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